The trial is evaluating VIR-5500 with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC.

ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.

Bayer (BAYRY) is running an Australian study called “Treatment Patterns and Characteristics of Patients Receiving Androgen Receptor Pathway Inhibitors in a Real-world Setting in Australia: A ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study ...

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...